Other substances

LbuCas13a N3.2

An RNA-guided ribonuclease.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

LbuCas13a N3.2 is a synthetic mRNA encoding a targeted ribonuclease and CRISPR RNA targeting the SARS-CoV-2 nucleocapsid gene. It is delivered in a polymer (PBAE) coating in a nebulized form in animal model studies. It was shown to reduce SARS-CoV-2 infection symptoms and viral replication in vitro and in a hamster model (Blanchard et al., 2021).

Synonyms

LbuC2c2 N3.2

 

Supporting references

Link Tested on Impact factor Notes Publication date
Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents
RNA Nucleocapsid protein Animal model In vitro Mixed substance 		Huh7 cells; Vero E6 cells; Syrian hamsters; SARS-CoV-2 strain USA-WA1/2020 36.56

The guided endonuclease (transfected into cells) significantly reduced SARS-CoV-2-induced cytopathic effect and decreased targeted viral gene copies in vitro. A nebulized formulation targeting SARS-CoV-2 nucleocapsid (N) gene delivered to a hamster model protected the animals from infection-related weight loss and decreased the N copy number.

 Feb/03/2021
Export (.csv)